Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.67 |
| ▸ | EGFR | P00533 | 4/20 | 0.63 |
| ▸ | AURKA | O14965 | 2/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.56 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5022330 | 0.92 | KDR (0.69) | KDREGFRAURKAHDAC3HDAC4 | |
| SCHEMBL5022508 | 0.92 | KDR (0.69) | KDREGFRAURKAHDAC3HDAC4 | |
| SCHEMBL5025447 | 0.92 | KDR (0.71) | KDREGFRAURKAHDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL5022938 | 0.92 | KDR (0.70) | KDREGFRAURKAHDAC3HDAC4 | |
| SCHEMBL5022354 | 0.90 | KDR (0.66) | KDREGFRAURKAHDAC3HDAC4 | |
| SCHEMBL5022265 | 0.87 | KDR (0.70) | KDREGFRAURKAAURKBIRAK4 | |
| SCHEMBL5025477 | 0.87 | KDR (0.64) | KDREGFRAURKAHDAC3HDAC4 | |
| SCHEMBL5090002 | 0.86 | KDR (0.63) | KDREGFRAURKAHDAC3HDAC4 | |
| SCHEMBL5026747 | 0.86 | KDR (0.60) | KDREGFRAURKAHDAC3HDAC4 | |
| SCHEMBL5016593 | 0.86 | KDR (0.62) | KDREGFRAURKAHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575966-B1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-10-29 | — | — | EP | disclosed |
| US-20060058325-A1 | Therapeutic quniazoline derivatives | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1575966-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058782-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058325-A1 | Therapeutic quniazoline derivatives | NQO2, ABL1, CYP3A7 | KDR 3166/4885EGFR 2724/4885AURKA 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.